Use of CTLA4 compound for achieving drug-free remission in subjects with early RA

摘要

The present invention is directed to methods and compositions for achieving drug-free remission in subjects with early RA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule until Disease Activity Score Calculator for Rheumatoid Arthritis (DAS)-defined remission is achieved and then withdrawing the RA therapy.